{"id":"et140203-t-cells","_chembl":{"chemblId":"CHEMBL5315099","moleculeType":"Unknown"},"modality":"Small molecule","_dailymed":null,"mechanism":{"explanation":"ET140203 T Cells appear to be an engineered T cell product, likely utilizing Eureka Therapeutics' proprietary T cell receptor or chimeric antigen receptor technology platforms. The specific antigen target and mechanism of T cell activation have not been publicly characterized.","oneSentence":"Engineered T cell therapy designed to target specific disease antigens, though the precise molecular target has not been publicly disclosed."},"_scrapedAt":"2026-03-28T04:37:23.761Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123502,"model":"claude-sonnet-4-5-20250929"},"description":"ET140203 T Cells is an investigational cell therapy product developed by Eureka Therapeutics Inc. currently in Phase 1 clinical development. As a T cell-based therapeutic, it represents an engineered cellular immunotherapy approach, though specific molecular targets and indications have not been publicly disclosed.","indications":{"approved":[{"status":"investigational","condition":"Unknown","patientPopulation":"Unknown"}]},"trialDetails":[{"nctId":"NCT04502082","phase":"PHASE1","title":"Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)","status":"TERMINATED","sponsor":"Eureka Therapeutics Inc.","startDate":"2021-04-14","conditions":"Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm","enrollment":8},{"nctId":"NCT04634357","phase":"PHASE1, PHASE2","title":"ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Eureka Therapeutics Inc.","startDate":"2022-07-19","conditions":"Hepatoblastoma, Hepatocellular Carcinoma (HCC), Liver Neoplasms","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":320968,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"ET140203 T Cells","genericName":"ET140203 T Cells","companyName":"Eureka Therapeutics Inc.","companyId":"eureka-therapeutics-inc","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}